Klabax

Clarithromycin, the active ingredient in Klabax, is a macrolide antibiotic presented as an oral tablet for oral use. It treats bacterial infections such as community‑acquired pneumonia, sinusitis, otitis media, skin infections and is used in Helicobacter pylori eradication regimens.

GNH USA supplies Klabax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin is a macrolide antibiotic that targets bacterial protein synthesis and is indicated for several infections. - Community‑acquired pneumonia: effective in treating bacterial pneumonia caused by susceptible organisms. - Acute bacterial sinusitis: resolves sinus infection symptoms. - Acute otitis media: clears middle‑ear bacterial infection. - Skin and soft‑tissue infections: eradicates susceptible skin pathogens. - Helicobacter pylori eradication: part of combination therapy to eliminate H. pylori.

Clarithromycin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Abdominal pain - Taste disturbance - Headache - Rash

Serious or Rare Side Effects: - Hepatotoxicity - QT interval prolongation - Severe allergic reactions (anaphylaxis) - Clostridioides difficile‑associated diarrhea - Stevens‑Johnson syndrome - Hepatic failure

When prescribing clarithromycin, several safety considerations are recommended. - Assess liver function: baseline hepatic enzymes should be evaluated before initiating therapy. - Monitor cardiac status: patients with known QT prolongation risk should be observed. - Avoid use in patients with known macrolide hypersensitivity: discontinue if allergic reaction occurs. - Consider drug interactions: review concomitant medications that affect CYP3A4. - Use caution in renal impairment: dose adjustment may be required per prescriber. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Clarithromycin interacts with several medicines; careful review is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir): may raise clarithromycin levels and increase toxicity. - Cisapride: co‑administration can precipitate serious cardiac arrhythmias. - Ergot derivatives (e.g., ergotamine): risk of ergotism due to increased plasma concentrations.

Moderate Interactions (Monitor Closely): - Statins metabolized by CYP3A4 (simvastatin, lovastatin): monitor for myopathy. - Warfarin: clarithromycin can enhance anticoagulant effect; monitor INR. - Theophylline: may increase theophylline concentrations, watch for toxicity.